AbbVie (ABBV)
(Delayed Data from NYSE)
$195.45 USD
-1.37 (-0.70%)
Updated Oct 3, 2024 04:00 PM ET
After-Market: $194.88 -0.57 (-0.29%) 7:58 PM ET
3-Hold of 5 3
C Value D Growth D Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$195.45 USD
-1.37 (-0.70%)
Updated Oct 3, 2024 04:00 PM ET
After-Market: $194.88 -0.57 (-0.29%) 7:58 PM ET
3-Hold of 5 3
C Value D Growth D Momentum D VGM
Zacks News
The Zacks Analyst Blog Highlights: Procter & Gamble, AbbVie, QUALCOMM, PepsiCo and CME Group
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Procter & Gamble, AbbVie, QUALCOMM, PepsiCo and CME Group
The Zacks Analyst Blog Highlights: AbbVie, Coherus BioSciences, Bluerock Residential Growth REIT, Huntington Ingalls Industries and Installed Building Products
by Zacks Equity Research
The Zacks Analyst Blog Highlights: AbbVie, Coherus BioSciences, Bluerock Residential Growth REIT, Huntington Ingalls Industries and Installed Building Products
Top Ranked Income Stocks to Buy for April 8th
by Zacks Equity Research
Here are four stocks with buy rank and strong income characteristics for investors to consider today, April 8th.
Large-Cap Pharma Stocks to Benefit in Post-Pandemic Market
by Kinjel Shah
The Zacks Large Cap Pharmaceuticals industry ranks in the top 13% of more than 250 Zacks industries.
AbbVie (ABBV) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
In the latest trading session, AbbVie (ABBV) closed at $75.27, marking a -0.61% move from the previous day.
Agilysys, Manpower, Eli Lilly and Company, Innoviva and AbbVie highlighted as Zacks Bull and Bear of the Day
by Zacks Equity Research
Agilysys, Manpower, Eli Lilly and Company, Innoviva and AbbVie highlighted as Zacks Bull and Bear of the Day
Analyzing Coronavirus-Hit US Economy on World Health Day: 6 Picks
by Sweta Killa
Let us examine the health of the U.S. economy this World Health Day amid the ongoing COVID-19 crisis and bring to investors notice some solid picks for a robust investment portfolio.
Signs of Coronavirus Slowdown Pep Up Wall Street: 5 Winners
by Tirthankar Chakraborty
Wall Street continues to build on a steep rebound in the previous session after lockdown strategy stabilized coronavirus outbreak in the United States and abroad.
Top Analyst Reports for Procter & Gamble, AbbVie & QUALCOMM
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Procter & Gamble (PG), AbbVie (ABBV) and QUALCOMM (QCOM).
Another Drug to Fight Coronavirus & 3 Picks
by Sejuti Banerjea
Another drug is being tested to kill the virus (if we can figure out administration on humans).
Novo Nordisk's Rybelsus Gets EU Nod for Type II Diabetes
by Zacks Equity Research
Novo Nordisk (NVO) gains the EU approval for Rybelsus to address adult patients with insufficiently-controlled type II diabetes for improving glycemic control as an adjunct to diet and exercise.
Improve Your Retirement Income with These 3 Top-Ranked Dividend Stocks - April 06, 2020
by Zacks Equity Research
The traditional ways to plan for your retirement may mean income can no longer cover expenses post-employment. But what if there was another option that could provide a steady, reliable source of income in your nest egg years?
Why AbbVie (ABBV) is a Top Dividend Stock for Your Portfolio
by Zacks Equity Research
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does AbbVie (ABBV) have what it takes? Let's find out.
The Extreme Risks of Trading Your Own Retirement Assets - April 02, 2020
by Zacks Equity Research
From understanding your risk tolerance to maintaining emotional control, achieving your retirement goals takes a much different investing approach than regular stock trading.
Powerful Proof Anyone Can Invest for an Early Retirement - April 01, 2020
by Zacks Equity Research
Achieving the financial freedom to retire early is a dream for most, but making that dream a reality isn't as tricky as it sounds. If you are willing to make some serious lifestyle changes and sacrifices, it can be possible.
AbbVie (ABBV) Gains As Market Dips: What You Should Know
by Zacks Equity Research
AbbVie (ABBV) closed the most recent trading day at $76.11, moving +1.16% from the previous trading session.
Buy this High-Yield Large Cap Pharma Stock for Income Amid Coronavirus
by Benjamin Rains
AbbVie (ABBV) stock popped on Tuesday. This is part of the global pharmaceutical giant's larger 20% surge in the last week as the market tries to mount a comeback amid the coronavirus uncertainty...
The Zacks Analyst Blog Highlights: Novartis, Teva, Gilead and AbbVie
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Novartis, Teva, Gilead and AbbVie
Lilly's Taltz Gets FDA Nod for Plaque Psoriasis in Children
by Zacks Equity Research
The FDA approves Eli Lilly's (LLY) sBLA for Taltz injection to treat pediatric patients with moderate to severe plaque psoriasis. Stock up.
Top Ranked Income Stocks to Buy for March 31st
by Zacks Equity Research
Here are three stocks with buy rank and strong income characteristics for investors to consider today, March 31st.
COVID-19 Claiming Lives But Therapeutics Could Be on the Way
by Sejuti Banerjea
The WHO's Solidarity testing project could be good news for the world.
3 Top-Ranked Dividend Stocks: A Smarter Way to Boost Your Retirement Income - March 30, 2020
by Zacks Equity Research
The traditional ways to plan for your retirement may mean income can no longer cover expenses post-employment. But what if there was another option that could provide a steady, reliable source of income in your nest egg years?
Bristol Myers (BMY) Clinches FDA Nod for MS Drug Zeposia
by Zacks Equity Research
The FDA approves Bristol Myers' (BMY) Zeposia for the treatment of adults with relapsing forms of multiple sclerosis.
Will Rescue Deal Impact Last? 4 Coronavirus-Proof Dividend Picks
by Urmimala Biswas
With the ongoing erratic movement of most stocks, it's a prudent idea for investors to go for dividend-paying stocks as a regular source of income.
Top Ranked Income Stocks to Buy for March 27th
by Zacks Equity Research
Here are three stocks with buy rank and strong income characteristics for investors to consider today, March 27th